Stockreport

Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biolog [Read more]